[B026] Clinical trial design

get
https://connect.patsnap.com/synapse/clinical-trial/design
Try in Sandbox

Obtain clinical trial design through clinical trial id or registry number

One of the parameters clinical_trial_id and register_number must be passed

Request Parameters

List of parameters supported by this API endpoint

NameTypeExampleDescription
clinical_trial_id
string202425a889e52ae802432a8295220e53
Clinical trial id, obtain this through clinical trial search interface
register_number
stringNCT06498986
register number

Response Schema

Structure of the API response data

Field NameTypeExampleDescription
data
object-
response data
masking
stringNone (Open Label)
Masking
outcome
array[ { "title": "Recommended Phase II Dose (RP2D)", "time_frame": "Up to approximately 24 months", "description": "The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-B01D1.", "outcome_type": "Primary" }, { "title": "Objective response rate (ORR)", "time_frame": "Up to approximately 24 months", "description": "ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.", "outcome_type": "Primary" } ]
Outcome Measures
title
stringRecommended Phase II Dose (RP2D)
Measure
time_frame
stringUp to approximately 24 months
Time Frame
description
stringThe RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-B01D1.
Description
outcome_type
stringPrimary
Outcome Type
allocation
stringN/A
Allocation
enrollment
array[ { "enrollment": "40" } ]
Enrollment
location
stringDomestic
Location. 'Domestic' means China.
enrollment
string98
Enrollment
enrollment_text
string国内:150
Enrollment Original Value
enrollment_type
stringAnticipated
Enrollment Type
start_date
object{ "time_ts": 1722470400000, "date_type": "Anticipated" }
Start Date
time_ts
integer<int64>1785542400000
Timestamp
date_type
stringAnticipated
Date Type, enumeration values: Anticipated, Actual
study_type
stringInterventional
Study Type, enumeration values: "Prevention", "Expanded Access", "Health Services Research", "Interventional", "Diagnosis", "Cause", "Observational", "Basic Science", "Unknown", "Others"
completion_date
object{ "time_ts": 1785542400000, "date_type": "Anticipated" }
Completion Date
primary_purpose
stringTreatment
Primary Purpose
register_number
stringNCT06498986
Trial Number
arm_intervention
array[ { "intervention": [ { "intervention_name": "BL-B01D1", "intervention_type": "Drug", "intervention_description": "Administration by intravenous infusion for a cycle of 3 weeks." }, { "intervention_name": "Osimertinib Mesylate Tablets", "intervention_type": "Drug", "intervention_description": "Oral administration, 80mg daily for a cycle of 3 weeks." } ], "design_group_type": "Experimental", "design_group_title": "BL-B01D1+Osimertinib Mesylate Tablets", "design_group_description": "Participants receive BL-B01D1+Osimertinib Mesylate Tablets in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons." } ]
Arms and Interventions
intervention
array[ { "intervention_name": "BL-B01D1", "intervention_type": "Drug", "intervention_description": "Administration by intravenous infusion for a cycle of 3 weeks." }, { "intervention_name": "Osimertinib Mesylate Tablets", "intervention_type": "Drug", "intervention_description": "Oral administration, 80mg daily for a cycle of 3 weeks." } ]
Intervention
intervention_name
stringBL-B01D1
Intervention Name
intervention_type
stringDrug
Intervention Type
intervention_description
stringAdministration by intravenous infusion for a cycle of 3 weeks.
Intervention Description
design_group_type
stringExperimental
Design Group Type
design_group_title
stringBL-B01D1+Osimertinib Mesylate Tablets
Design Group Title
design_group_description
stringParticipants receive BL-B01D1+Osimertinib Mesylate Tablets in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
Design Group Description
clinical_trial_id
string202425a889e52ae802432a8295220e53
Clinical Trial ID
first_posted_date
integer<int64>1720742400000
First Posted Date
intervention_model
stringSingle Group Assignment
Intervention Model
primary_completion_date
object{ "time_ts": 1785542400000, "date_type": "Anticipated" }
Primary Completion Date
status
Required
booleanfalse
Status
error_msg
stringThe request parameter format is incorrect!
Error Message
error_code
Required
integer0
Error Code

Success Response Example

Example of a successful API response

JSON
{
  "data": {
    "masking": "None (Open Label)",
    "outcome": [
      {
        "title": "Recommended Phase II Dose (RP2D)",
        "time_frame": "Up to approximately 24 months",
        "description": "The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-B01D1.",
        "outcome_type": "Primary"
      }
    ],
    "allocation": "N/A",
    "enrollment": [
      {
        "location": "Domestic",
        "enrollment": 98,
        "enrollment_text": "国内:150",
        "enrollment_type": "Anticipated"
      }
    ],
    "start_date": {
      "time_ts": 1785542400000,
      "date_type": "Anticipated"
    },
    "study_type": "Interventional",
    "completion_date": {
      "time_ts": 1785542400000,
      "date_type": "Anticipated"
    },
    "primary_purpose": "Treatment",
    "register_number": "NCT06498986",
    "arm_intervention": [
      {
        "intervention": [
          {
            "intervention_name": "BL-B01D1",
            "intervention_type": "Drug",
            "intervention_description": "Administration by intravenous infusion for a cycle of 3 weeks."
          }
        ],
        "design_group_type": "Experimental",
        "design_group_title": "BL-B01D1+Osimertinib Mesylate Tablets",
        "design_group_description": "Participants receive BL-B01D1+Osimertinib Mesylate Tablets in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons."
      }
    ],
    "clinical_trial_id": "202425a889e52ae802432a8295220e53",
    "first_posted_date": 1720742400000,
    "intervention_model": "Single Group Assignment",
    "primary_completion_date": {
      "time_ts": 1785542400000,
      "date_type": "Anticipated"
    }
  },
  "status": true,
  "error_code": 0
}

Error Codes

List of possible error codes returned by this endpoint

Business Errors

Error CodeDescription
68300004Invalid parameter!
68300005Search api failure!
68300006Analytic basic access error!
68300007Bad request!
68300008Service error, please try again later!
68300010The file does not comply with upload specifications!

Platform Errors

Error CodeDescription
67200001API call exceeds the total limit set by the platform!
67200002Quota exceeds the limit!
67200003Access token expired or authentication error!
67200004No permission or API package quota has exceeded the limit!
67200005Insufficient balance, call failed!
67200006This client has expired and call failed!
67200007Exceeded the call limit, call failed!

HTTP Status Codes

Status CodeDescription
0Success
401Unauthorized
403Forbidden
404Not Found